Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Mirati Therapeutics

Mirati said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed on questions about its market opportunity. The post Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up appeared first on Investor's Business Daily.

Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up

Amgen Inc. (NASDAQ:AMGN ) World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease Conference Call December 5, 2022 8:00 AM ET Company Participants David Reese - Executive Vice President, Research and Development Narimon Honarpour - Vice President, Clinical Development Conference Call Participants Umer Raffat - Evercore Matthew Harrison - Morgan Stanley Michael Yee - Jefferies Jay Olson - Oppenheimer Salveen Richter - Goldman Sachs Evan Seigerman - BMO Capital Geoff Meacham - Bank of America Colin Bristow - UBS Mohit Bansal - Wells Fargo Michael Schmidt - Guggenheim Partners David Risinger - SVB Securities Chris Schott - JPMorgan Chase Matt Phipps - William Blair Trung Huynh - Credit Suisse Colin Bristow - UBS Operator Hello and welcome. My name is Alex and I will be your conference facilitator today for the Amgen Analyst and Investor Conference Call from the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease Conference.

Amgen Inc. (AMGN) World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease Conference (Transcript)

Johnson & Johnson

Sanofi

Johnson & Johnson dropped out of the bidding process for Horizon Therapeutics, pushing HZNP stock into the red on Monday. The post Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi appeared first on Investor's Business Daily.

Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi

Devon Energy

Lockheed Martin

Occidental Petroleum

Petroleo Brasileiro

T-Mobile US

Exxon Mobil

It makes sense if you haven't been thinking much about Christmas stocks. You really can't be blamed for not being in the Christmas spirit this year.

7 Christmas Stocks to Buy for Happy Holidays

Amgen's dividend yield is materially higher than the S&P 500 index's yield.

Is Amgen Stock a Buy for Income Investors?

Amgen stock could get a fresh boost Thursday after the company unveiled promising results for its obesity treatment. The post Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly appeared first on Investor's Business Daily.

Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly

AMG 133 is a First-in-Class Investigational Bispecific Molecule That Activates GLP-1R and Inhibits GIPR Phase 1 Results Showed up to 14.5% Reduction in Body Weight at the Highest Dose After 12 Weeks Initiating Phase 2 Study in Early 2023 THOUSAND OAKS, Calif. , Dec. 1, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule.

AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022

Horizon Pharma

Horizon said Tuesday it's considering potential offers from three Big Pharma stalwarts, sending HZNP stock soaring more than 30% after hours. The post Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi appeared first on Investor's Business Daily.

Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi

Start Time: 11:20 January 1, 0000 11:58 AM ET Amgen Inc. (NASDAQ:AMGN ) Evercore ISI HealthCONx Conference November 29, 2022, 11:20 AM ET Company Participants David Reese - EVP, Research and Development Arvind Sood - VP, IR Conference Call Participants Umer Raffat - Evercore Umer Raffat Excellent. Thank you, guys.

Amgen Inc. (AMGN) Presents at Evercore ISI HealthCONx Conference (Transcript)

CVS Health

Elevance Health Inc

Home Depot

Wells Fargo

The third quarter of 2022 was another discouraging period for investors. Inflation kept going strong, the Federal Reserve continued raising interest rates and even the housing market began showing signs of weakness as consumers were slammed by the combination of rising costs and increasing mortgage rates.

The Most-Sold Guru Stocks of the 3rd Quarter

THOUSAND OAKS, Calif. , Nov. 28, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m.

AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022

2 top health care dividend stocks to check out ahead of December 2022.

Best Dividend Stocks To Buy Now? 2 To Watch Before December 2022

Bristol-Myers

Eli Lilly

Pfizer

Among the 19 companies that are expected to announce annual dividend increases in December are drugmakers Eli Lilly, Pfizer, Bristol Myers Squibb, and Amgen. Investors are also waiting for Merck's increase. We'll see several nice increases in December from other companies as well: Nucor, Mastercard, and Broadcom are all expected to announce 10%+ boosts.

4 Pharmaceutical Companies Among 19 To Announce Annual Dividend Increases In December

THOUSAND OAKS, Calif. , Nov. 23, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 11:20 a.m.

AMGEN ANNOUNCES WEBCAST OF 2022 EVERCORE ISI HEALTHCARE CONFERENCE

Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

Key Factors Driving Amgen's (AMGN) Outperformance This Year

So far, all signals point to a resounding yes. Amgen's obesity drug, AMG 133, completed a successful phase I trial, which helped lift the company's stock price.

Amgen's New Obesity Drug: Will Amgen Stock Skyrocket Through FDA Trials?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?

AbbVie

3 pharmaceutical stocks to watch in the stock market right now.

3 Pharmaceutical Stocks For Your November 2022 Watchlist

Amgen Inc. (NASDAQ:AMGN ) Credit Suisse 31st Annual Healthcare Conference Call November 9, 2022 3:50 PM ET Company Participants Peter Griffith - EVP and CFO David Reese - EVP, Research and Development Conference Call Participants Matthew Weston - Credit Suisse Matthew Weston Good afternoon, everyone [indiscernible] and Dave Reese, EVP of R&D. My name is Matthew Weston.

Amgen Inc. (AMGN) Presents at Credit Suisse 31st Annual Healthcare Conference Transcript

Amgen, Inc. (NASDAQ:AMGN ) American Heart Association (AHA) Scientific Sessions 2022 November 8, 2022 4:30 AM ET Company Participants David Reese - EVP, Research & Development Arvind Sood - VP, IR Narimon Honarpour - Head, Clinical Development for Cardiometabolic Disease Marc Sabatine - Professor of Medicine, Harvard Medical School Conference Call Participants Michael Yee - Jefferies Matthew Phipps - William Blair & Company Christopher Schott - JPMorgan Chase & Co. Salveen Richter - Goldman Sachs Michael DiFiore - Evercore ISI Robyn Karnauskas - Truist Securities Conor MacKay - BMO Capital Markets Carter Gould - Barclays Bank Colin Bristow - UBS Yaron Werber - Cowen Geoff Meacham - Bank of America Merrill Lynch Jay Olson - Oppenheimer Matthew Harrison - Morgan Stanley Dane Leone - Raymond James & Associates David Risinger - SVB Securities Mohit Bansal - Wells Fargo Securities Operator My name is , and I will be your conference facilitator today for Amgen's Analyst and Investor Conference Call at the 2022 American Heart Association Meeting. [Operator Instructions].

Amgen, Inc. (AMGN) American Heart Association (AHA) Scientific Sessions 2022 Transcript

These two top biopharma stocks are crushing the 2022 bear market.

2 Ultra-Safe Passive Income Stocks to Buy Right Now

Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly. The post How Amgen Is Closing In On Rivals Novo Nordisk, Eli Lilly With Obesity Drug appeared first on Investor's Business Daily.

How Amgen Is Closing In On Rivals Novo Nordisk, Eli Lilly With Obesity Drug

AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022

New Real-World Evidence Highlights AMGEVITA® Utilization, Treatment Satisfaction and Persistence in European Patients New Data From First-in-Class Treatment TAVNEOS®, Evaluating Renal Function Among Adults Living With Severe Active ANCA-Associated Vasculitis THOUSAND OAKS, Calif. , Nov. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will be presented at the annual American College of Rheumatology Convergence (ACR), taking place in Philadelphia on Nov. 10-14, 2022.

AMGEN TO PRESENT NEW RESEARCH ACROSS SERIOUS INFLAMMATORY AND BONE DISEASES AT ACR 2022

Olpasiran Reduced Lipoprotein(a) Levels by More Than 95% in Patients With Established ASCVD Amgen is Initiating a Phase 3 Cardiovascular Outcomes Trial Based on These Results Data Simultaneously Published in the New England Journal of Medicine THOUSAND OAKS, Calif. , Nov. 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of investigational olpasiran (formerly AMG 890) in adults with elevated lipoprotein(a) [Lp(a)] levels (>150 nmol/L) and a history of atherosclerotic cardiovascular disease (ASCVD).

News for Amgen Stock (AMGN)